JMP Securities Reaffirms Market Outperform Rating for Taysha Gene Therapies (NASDAQ:TSHA)

JMP Securities reaffirmed their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Several other research firms also recently issued reports on TSHA. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Price Performance

TSHA stock traded up $0.17 during trading on Monday, reaching $2.58. 5,758,382 shares of the company were exchanged, compared to its average volume of 2,742,524. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock's 50 day moving average price is $1.59 and its 200 day moving average price is $1.80. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a market cap of $529.04 million, a P/E ratio of 4.10 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to analysts' expectations of $2.05 million. As a group, analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its holdings in shares of Taysha Gene Therapies by 7.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock worth $34,600,000 after purchasing an additional 1,349,999 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in Taysha Gene Therapies by 128.6% in the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock worth $18,078,000 after buying an additional 5,877,778 shares during the last quarter. Vanguard Group Inc. grew its holdings in Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock valued at $15,409,000 after buying an additional 641,305 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies during the 4th quarter worth about $8,650,000. Finally, Geode Capital Management LLC boosted its position in shares of Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after acquiring an additional 9,591 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.